Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
Conditions: Neoadjuvant Chemotherapy; Resectable Pancreatic Cancer Interventions: Drug: irinotecan liposome + oxaliplatin + 5-FU / LV; Drug: Adebellizumab Sponsors: Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Research